First Dallas Securities Inc. increased its position in Boston Scientific Co. (NYSE:BSX) by 5.1% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,445 shares of the medical equipment provider’s stock after acquiring an additional 795 shares during the period. First Dallas Securities Inc.’s holdings in Boston Scientific were worth $631,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BSX. Athena Capital Advisors LLC acquired a new position in shares of Boston Scientific in the 4th quarter worth approximately $28,000. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its stake in Boston Scientific by 60.0% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 800 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 300 shares in the last quarter. Essex Savings Bank bought a new position in Boston Scientific during the first quarter valued at approximately $31,000. Hanson McClain Inc. grew its holdings in shares of Boston Scientific by 107.6% in the first quarter. Hanson McClain Inc. now owns 903 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 468 shares during the last quarter. Finally, Sontag Advisory LLC bought a new stake in Boston Scientific in the fourth quarter valued at $37,000. Institutional investors and hedge funds own 90.68% of the company’s stock.

A number of research firms have issued reports on BSX. BTIG Research restated a “buy” rating on shares of Boston Scientific in a research note on Thursday, April 25th. Canaccord Genuity lowered their price target on Boston Scientific from $45.00 to $43.00 and set a “buy” rating on the stock in a report on Wednesday, April 17th. Evercore ISI raised Boston Scientific from an “in-line” rating to an “outperform” rating and set a $36.20 price objective on the stock in a report on Monday, May 13th. Finally, Needham & Company LLC restated a “buy” rating and set a $43.00 price target on shares of Boston Scientific in a report on Monday, May 13th. Three research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $41.87.

In other news, SVP Maulik Nanavaty sold 3,038 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $36.74, for a total transaction of $111,616.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP David A. Pierce sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $37.10, for a total value of $185,500.00. The disclosure for this sale can be found here. Insiders sold a total of 39,020 shares of company stock worth $1,488,045 over the last ninety days. Corporate insiders own 0.66% of the company’s stock.

Shares of BSX stock opened at $40.42 on Monday. The company has a market cap of $56.21 billion, a PE ratio of 27.50, a price-to-earnings-growth ratio of 2.40 and a beta of 0.75. Boston Scientific Co. has a 12-month low of $31.56 and a 12-month high of $41.99. The company has a quick ratio of 1.12, a current ratio of 1.39 and a debt-to-equity ratio of 0.82.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 24th. The medical equipment provider reported $0.35 EPS for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.01). The company had revenue of $2.49 billion for the quarter, compared to analyst estimates of $2.54 billion. Boston Scientific had a net margin of 18.08% and a return on equity of 24.65%. Boston Scientific’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.33 EPS. On average, equities research analysts expect that Boston Scientific Co. will post 1.55 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This story was published by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Further Reading: Cost of Capital

Want to see what other hedge funds are holding BSX? Visit to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with's FREE daily email newsletter.